PIM1 and neoplasm: In patient-derived xenografts harbouring the common activating ALK mutations (F1174L, F1245C), combinatorial ALK (ceritinib) and PIM1 (AZD1208) inhibition displayed greater anti-tumour efficacy than either agent in isolation [149].